Details
Stereochemistry | ACHIRAL |
Molecular Formula | C23H24FN3O2S |
Molecular Weight | 425.519 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
FC1=CC=C(C=C1)N2CCN(CCCN3C4=CC=CC5=C4C(=CC=C5)S3(=O)=O)CC2
InChI
InChIKey=VGIGHGMPMUCLIQ-UHFFFAOYSA-N
InChI=1S/C23H24FN3O2S/c24-19-8-10-20(11-9-19)26-16-14-25(15-17-26)12-3-13-27-21-6-1-4-18-5-2-7-22(23(18)21)30(27,28)29/h1-2,4-11H,3,12-17H2
Fananserin is a potential antipsychotic compound with a high affinity for both D4 and 5-HT2A receptors, and negligible affinity for D2 receptors. Fananserin has been researched for the treatment of schizophrenia. Fananserin was the first selective D4/5-HT2A antagonist to undergo clinical trials for schizophrenia. It has a high affinity for D4 (Ki 2.9 nM) and 5-HT2A (Ki 0.37 nM) receptors and is over 100-fold selective versus H1, a1 adrenergic, 5-HT1A and D2 dopamine receptors. Development of this compound was halted following
phase II clinical trials due to lack of efficacy.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL219 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10080558 |
2.93 nM [Ki] | ||
0.37 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10080558
Treatment of schizophrenia: doses of fananserin reached 250 mg b.i.d. over 28 days, starting with an 8-day escalation.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8386088
In in vitro experiments, RP 62203 (Fananserin) displaced [125I]AMIK from 5-HT2 receptors with an IC50 of 0.21 nM in rat frontal cortex.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C66885
Created by
admin on Fri Dec 15 15:55:29 GMT 2023 , Edited by admin on Fri Dec 15 15:55:29 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
127625-29-0
Created by
admin on Fri Dec 15 15:55:29 GMT 2023 , Edited by admin on Fri Dec 15 15:55:29 GMT 2023
|
PRIMARY | |||
|
Fananserin
Created by
admin on Fri Dec 15 15:55:29 GMT 2023 , Edited by admin on Fri Dec 15 15:55:29 GMT 2023
|
PRIMARY | |||
|
C80768
Created by
admin on Fri Dec 15 15:55:29 GMT 2023 , Edited by admin on Fri Dec 15 15:55:29 GMT 2023
|
PRIMARY | |||
|
SUB07507MIG
Created by
admin on Fri Dec 15 15:55:29 GMT 2023 , Edited by admin on Fri Dec 15 15:55:29 GMT 2023
|
PRIMARY | |||
|
38QJ762ET6
Created by
admin on Fri Dec 15 15:55:29 GMT 2023 , Edited by admin on Fri Dec 15 15:55:29 GMT 2023
|
PRIMARY | |||
|
100000081780
Created by
admin on Fri Dec 15 15:55:29 GMT 2023 , Edited by admin on Fri Dec 15 15:55:29 GMT 2023
|
PRIMARY | |||
|
60785
Created by
admin on Fri Dec 15 15:55:29 GMT 2023 , Edited by admin on Fri Dec 15 15:55:29 GMT 2023
|
PRIMARY | |||
|
DTXSID8046743
Created by
admin on Fri Dec 15 15:55:29 GMT 2023 , Edited by admin on Fri Dec 15 15:55:29 GMT 2023
|
PRIMARY | |||
|
II-41
Created by
admin on Fri Dec 15 15:55:29 GMT 2023 , Edited by admin on Fri Dec 15 15:55:29 GMT 2023
|
PRIMARY | |||
|
7077
Created by
admin on Fri Dec 15 15:55:29 GMT 2023 , Edited by admin on Fri Dec 15 15:55:29 GMT 2023
|
PRIMARY | |||
|
CHEMBL83894
Created by
admin on Fri Dec 15 15:55:29 GMT 2023 , Edited by admin on Fri Dec 15 15:55:29 GMT 2023
|
PRIMARY |
ACTIVE MOIETY